Assignee
IMMUNIC AG
DE·7 granted patents·10 pending applications·3 citations·filing 2018–2024
Top patents by PatentIndex Score
17 records- 0190US11376232B2Vidofludimus for use in the treatment or prevention of viral diseasesIMMUNIC AG·Filed 2021·Granted Jul 5, 2022·2 cites·29 claims
- 0287US11877994B2Treatment of multiple sclerosis comprising DHODH inhibitorsIMMUNIC AG·Filed 2021·Granted Jan 23, 2024·1 cites·18 claims
- 0381US12433860B2Treatment of multiple sclerosis comprising DHODH inhibitorsIMMUNIC AG·Filed 2023·Granted Oct 7, 2025·0 cites·18 claims
- 0479US2025120931A1Treatment of multiple schlerosis comprising dhodh inhibitorsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 0575US11877995B2Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseasesIMMUNIC AG·Filed 2022·Granted Jan 23, 2024·0 cites·34 claims
- 0673US2024100005A1Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune DiseasesIMMUNIC AG·Filed 2023·Application pending·0 cites
- 0767US12167994B2Vidofludimus for use in the treatment or prevention of viral diseasesIMMUNIC AG·Filed 2022·Granted Dec 17, 2024·0 cites·19 claims
- 0864US2025136542A1Calcium salt polymorphs as anti-inflammatory, immunodulatory and anti-proliferative agentsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 0963US12037305B2Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agentsIMMUNIC AG·Filed 2019·Granted Jul 16, 2024·0 cites·16 claims
- 1063US2024335405A1Vidofludimus and related structures acting as nurr1 agonistsIMMUNIC AG·Filed 2024·Application pending·0 cites
- 1162US2025243190A1New deuterated rorgamma/rorgammat inverse agonistsIMMUNIC AG·Filed 2023·Application pending·0 cites
- 1260US2025066290A1Dhodh inhibitors containing a carboxylic acid bioisostereIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1360US2025032527A1Medical use of n4-hydroxy citicoline compoundsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1458US2024368145A1Methods for treating cancerIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1557US2024199535A1Deuterated dhodh inhibitorsIMMUNIC AG·Filed 2022·Application pending·0 cites
- 1654US2020360324A1Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune DiseasesIMMUNIC AG·Filed 2018·Application pending·0 cites
- 1741US11292788B2IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammationIMMUNIC AG·Filed 2018·Granted Apr 5, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when IMMUNIC AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →